Nuvectis Pharma provides highlights from NXP900 poster presentations

Nuvectis Pharma (NVCT) provided highlights for NXP900 poster presentations that took place last week at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA. NXP900 Clinical Safety, PKPD and CYP450 Interactions: XP900 elicited a robust pharmacodynamic response at doses greater than or equal to150 mg/day; In a clinical drug-drug interaction study in healthy volunteers NXP900 did not induce the activity of key CYP450 enzymes, a key consideration for the combination strategy. NXP900 Inhibits Tumor Growth in FAT1-mutated Xenograft Models: NXP900 inhibits YAP1 nuclear localization and cell proliferation at low nM concentration in FAT1-mutated squamous carcinoma cells; NXP900 inhibits tumor growth in FAT1-mutated squamous xenograft models.